Laura E Targownik1,2, Gilaad G Kaplan3, Julia Witt4, Charles N Bernstein1, Harminder Singh1,5, Aruni Tennakoon1, Antonio Aviña Zubieta6, Stephanie B Coward3, Jennifer Jones7, M Ellen Kuenzig8, Sanjay K Murthy9, Geoffrey C Nguyen10,2, Juan Nicolás Peña-Sánchez11, Eric I Benchimol8,12,13. 1. Section of Gastroenterology, Division of Internal Medicine, Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. 2. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. 3. Department of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Calgary, Alberta, Canada. 4. Department of Economics, Faculty of Arts, University of Manitoba, Winnipeg, Manitoba, Canada. 5. Department of Community Health Sciences, Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. 6. Arthritis Research Centre, University of British Columbia, Vancouver British Columbia, Canada. 7. Department of Internal Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. 8. Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Eastern Ontario, Children's Hospital of Eastern Ontario IBD Centre, Ottawa, Ontario, Canada. 9. The Ottawa Hospital IBD Centre, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada. 10. Mount Sinai Hospital Inflammatory Bowel Disease Centre, University of Toronto, Toronto, Ontario, Canada. 11. Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. 12. Department of Pediatrics and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada. 13. Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
Abstract
OBJECTIVES: The prevalence of inflammatory bowel disease (IBD) is increasing. The total direct costs of IBD have not been assessed on a population-wide level in the era of biologic therapy. DESIGN: We identified all persons with IBD in Manitoba between 2005 and 2015, with each matched to 10 controls on age, sex, and area of residence. We enumerated all hospitalizations, outpatient visits and prescription medications including biologics, and their associated direct costs. Total and per capita annual IBD-attributable costs and health care utilization (HCU) were determined by taking the difference between the costs/HCU accrued by an IBD case and their controls. Generalized linear modeling was used to evaluate trends in direct costs and Poisson regression for trends in HCU. RESULTS: The number of people with IBD in Manitoba increased from 6,323 to 7,603 between 2005 and 2015. The total per capita annual costs attributable to IBD rose from $3,354 in 2005 to $7,801 in 2015, primarily driven by an increase in per capita annual anti-tumor necrosis factor costs, which rose from $181 in 2005 to $5,270 in 2015. There was a significant decline in inpatient costs for CD ($99 ± 25/yr. P < 0.0001), but not for ulcerative colitis ($8 increase ±$18/yr, P = 0.63). DISCUSSION: The direct health care costs attributable to IBD have more than doubled over the 10 years between 2005 and 2015, driven mostly by increasing expenditures on biological medications. IBD-attributable hospitalization costs have declined modestly over time for persons with CD, although no change was seen for patients with ulcerative colitis.
OBJECTIVES: The prevalence of inflammatory bowel disease (IBD) is increasing. The total direct costs of IBD have not been assessed on a population-wide level in the era of biologic therapy. DESIGN: We identified all persons with IBD in Manitoba between 2005 and 2015, with each matched to 10 controls on age, sex, and area of residence. We enumerated all hospitalizations, outpatient visits and prescription medications including biologics, and their associated direct costs. Total and per capita annual IBD-attributable costs and health care utilization (HCU) were determined by taking the difference between the costs/HCU accrued by an IBD case and their controls. Generalized linear modeling was used to evaluate trends in direct costs and Poisson regression for trends in HCU. RESULTS: The number of people with IBD in Manitoba increased from 6,323 to 7,603 between 2005 and 2015. The total per capita annual costs attributable to IBD rose from $3,354 in 2005 to $7,801 in 2015, primarily driven by an increase in per capita annual anti-tumor necrosis factor costs, which rose from $181 in 2005 to $5,270 in 2015. There was a significant decline in inpatient costs for CD ($99 ± 25/yr. P < 0.0001), but not for ulcerative colitis ($8 increase ±$18/yr, P = 0.63). DISCUSSION: The direct health care costs attributable to IBD have more than doubled over the 10 years between 2005 and 2015, driven mostly by increasing expenditures on biological medications. IBD-attributable hospitalization costs have declined modestly over time for persons with CD, although no change was seen for patients with ulcerative colitis.
Authors: Siddharth Singh; Alexander S Qian; Nghia H Nguyen; Stephanie K M Ho; Jiyu Luo; Vipul Jairath; William J Sandborn; Christopher Ma Journal: Inflamm Bowel Dis Date: 2022-03-02 Impact factor: 7.290
Authors: Konstantinos Gkikas; Konstantinos Gerasimidis; Simon Milling; Umer Z Ijaz; Richard Hansen; Richard K Russell Journal: Nutrients Date: 2020-07-07 Impact factor: 5.717
Authors: Carol A Hitchon; Randy Walld; Christine A Peschken; Charles N Bernstein; James M Bolton; Renée El-Gabalawy; John D Fisk; Alan Katz; Lisa M Lix; James Marriott; Scott B Patten; Jitender Sareen; Alexander Singer; Ruth Ann Marrie Journal: Arthritis Care Res (Hoboken) Date: 2021-01 Impact factor: 4.794
Authors: Jessica Amankwah Osei; Juan Nicolás Peña-Sánchez; Sharyle A Fowler; Nazeem Muhajarine; Gilaad G Kaplan; Lisa M Lix Journal: J Can Assoc Gastroenterol Date: 2021-03-16
Authors: Fernando García-Rodríguez; Augusto Gamboa-Alonso; Sol Jiménez-Hernández; Lucero Ochoa-Alderete; Valeria Alejandra Barrientos-Martínez; Neri Alejandro Alvarez-Villalobos; Gabriela Andrea Luna-Ruíz; Ingris Peláez-Ballestas; Ana Victoria Villarreal-Treviño; Manuel Enrique de la O-Cavazos; Nadina Rubio-Pérez Journal: Pediatr Rheumatol Online J Date: 2021-10-09 Impact factor: 3.054
Authors: María Chaparro; Ana Garre; Andrea Núñez Ortiz; María Teresa Diz-Lois Palomares; Cristina Rodríguez; Sabino Riestra; Milagros Vela; José Manuel Benítez; Estela Fernández Salgado; Eugenia Sánchez Rodríguez; Vicent Hernández; Rocío Ferreiro-Iglesias; Ángel Ponferrada Díaz; Jesús Barrio; José María Huguet; Beatriz Sicilia; María Dolores Martín-Arranz; Xavier Calvet; Daniel Ginard; Inmaculada Alonso-Abreu; Luis Fernández-Salazar; Pilar Varela Trastoy; Montserrat Rivero; Isabel Vera-Mendoza; Pablo Vega; Pablo Navarro; Mónica Sierra; José Luis Cabriada; Mariam Aguas; Raquel Vicente; Mercè Navarro-Llavat; Ana Echarri; Fernando Gomollón; Elena Guerra Del Río; Concepción Piñero; María José Casanova; Katerina Spicakova; Jone Ortiz de Zarate; Emilio Torrella Cortés; Ana Gutiérrez; Horacio Alonso-Galán; Álvaro Hernández-Martínez; José Miguel Marrero; Rufo Lorente Poyatos; Margalida Calafat; Lidia Martí Romero; Pilar Robledo; Orencio Bosch; Nuria Jiménez; María Esteve Comas; José María Duque; Ana María Fuentes Coronel; Manuela Josefa Sampedro; Eva Sesé Abizanda; Belén Herreros Martínez; Liliana Pozzati; Hipólito Fernández Rosáenz; Belén Crespo Suarez; Pilar López Serrano; Alfredo J Lucendo; Margarita Muñoz Vicente; Fernando Bermejo; José Joaquín Ramírez Palanca; Margarita Menacho; Amalia Carmona; Raquel Camargo; Sandra Torra Alsina; Nuria Maroto; Juan Nerín de la Puerta; Elena Castro; Ignacio Marín-Jiménez; Belén Botella; Amparo Sapiña; Noelia Cruz; José Luis F Forcelledo; Abdel Bouhmidi; Carlos Castaño-Milla; Verónica Opio; Isabel Nicolás; Marcos Kutz; Alfredo Abraldes Bechiarelli; Jordi Gordillo; Yolanda Ber; Yolanda Torres Domínguez; María Teresa Novella Durán; Silvia Rodríguez Mondéjar; Francisco J Martínez-Cerezo; Lilyan Kolle; Miriam Sabat; Cesar Ledezma; Eduardo Iyo; Óscar Roncero; Rebeca Irisarri; Laia Lluis; Isabel Blázquez Gómez; Eva María Zapata; María José Alcalá; Cristina Martínez Pascual; María Montealegre; Laura Mata; Ana Monrobel; Alejandro Hernández Camba; Luis Hernández; María Tejada; Alberto Mir; María Luisa Galve; Marta Soler; Daniel Hervías; José Antonio Gómez-Valero; Manuel Barreiro-de Acosta; Fernando Rodríguez-Artalejo; Esther García-Esquinas; Javier P Gisbert Journal: J Clin Med Date: 2021-06-29 Impact factor: 4.964